Suppr超能文献

嗅觉受体家族 7 亚家族 C 成员 1 是结肠癌起始细胞的新型标志物,也是免疫治疗的有效靶点。

Olfactory Receptor Family 7 Subfamily C Member 1 Is a Novel Marker of Colon Cancer-Initiating Cells and Is a Potent Target of Immunotherapy.

机构信息

Department of Pathology, Sapporo Medical University School of Medicine, Chuo-Ku, Sapporo, Japan.

Department of Surgery, Sapporo Medical University School of Medicine, Chuo-Ku, Sapporo, Japan.

出版信息

Clin Cancer Res. 2016 Jul 1;22(13):3298-309. doi: 10.1158/1078-0432.CCR-15-1709. Epub 2016 Feb 9.

Abstract

PURPOSE

Cancer-initiating cells (CICs) are thought to be essential for tumor maintenance, recurrence, and distant metastasis, and they are therefore reasonable targets for cancer therapy. Cancer immunotherapy is a novel approach to target cancer. In this study, we aimed to establish novel CIC-targeting immunotherapy.

EXPERIMENTAL DESIGN

Colorectal cancer (CRC) CICs were isolated as side population (SP) cells. The gene expression profile of CRC CICs was analyzed by cDNA microarray and RT-PCR. Protein expression of olfactory receptor family 7 subfamily C member 1 (OR7C1) were analyzed by Western blot and immunohistochemical staining. The functions of OR7C1 were analyzed by gene overexpression and gene knockdown using siRNAs. OR7C1-positive cells were isolated by a flow cytometer and analyzed. CTLs specific for OR7C1 peptide were generated, and the antitumor effect was addressed by mice adoptive transfer model.

RESULTS

OR7C1 has essential roles in the maintenance of colon CICs, and the OR7C1-positive population showed higher tumorigenicity than that of the OR7C1-negative population, indicating that OR7C1 is a novel functional marker for colon CIC. Immunohistochemical staining revealed that OR7C1 high expression was correlated with poorer prognosis in CRC patients. OR7C1-derived antigenic peptide-specific CTLs showed specific cytotoxicity for CICs, and an OR7C1-specific CTL clone showed a greater antitumor effect than did a CTL clone targeting all cancer cells in a CTL adoptive transfer mouse model.

CONCLUSIONS

OR7C1 is a novel marker for colon CICs and can be a target of potent CIC-targeting immunotherapy. Clin Cancer Res; 22(13); 3298-309. ©2016 AACR.

摘要

目的

癌症起始细胞(CICs)被认为对肿瘤的维持、复发和远处转移至关重要,因此它们是癌症治疗的合理靶点。癌症免疫疗法是一种针对癌症的新方法。在这项研究中,我们旨在建立新的 CIC 靶向免疫疗法。

实验设计

分离结直肠癌(CRC)CIC 作为侧群(SP)细胞。通过 cDNA 微阵列和 RT-PCR 分析 CRC CIC 的基因表达谱。使用 Western blot 和免疫组织化学染色分析嗅觉受体家族 7 亚家族 C 成员 1(OR7C1)的蛋白表达。通过使用 siRNA 进行基因过表达和基因敲低来分析 OR7C1 的功能。通过流式细胞仪分离 OR7C1 阳性细胞并进行分析。生成针对 OR7C1 肽的 CTL,并通过小鼠过继转移模型解决其抗肿瘤作用。

结果

OR7C1 在结肠 CIC 的维持中起重要作用,OR7C1 阳性群体比 OR7C1 阴性群体具有更高的致瘤性,表明 OR7C1 是结肠 CIC 的新型功能标志物。免疫组织化学染色显示,OR7C1 高表达与 CRC 患者的预后不良相关。OR7C1 衍生的抗原肽特异性 CTL 对 CIC 表现出特异性细胞毒性,并且在 CTL 过继转移小鼠模型中,OR7C1 特异性 CTL 克隆比针对所有癌细胞的 CTL 克隆具有更大的抗肿瘤作用。

结论

OR7C1 是结肠 CIC 的新型标志物,可作为有效的 CIC 靶向免疫治疗的靶点。Clin Cancer Res; 22(13); 3298-309. ©2016 AACR.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验